SNP biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer

OBJECTIVE: Based on our previous findings that postmenopausal women with estrone (E1) and estradiol (E2) concentrations at or above 1.3 pg/mL and 0.5 pg/mL, respectively, after six months of adjuvant anastrozole therapy had a 3-fold risk of recurrence, we aimed to identify a SNP-based model that wou...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacogenet Genomics
Main Authors: Ingle, James N., Kalari, Krishna R., Barman, Poulami, Shepherd, Lois E., Ellis, Matthew J., Goss, Paul E., Buzdar, Aman U., Robson, Mark E., Cairns, Junmei, Carlson, Erin E., Casey, Abraham Eyman, Hoskin, Tanya L., Goodnature, Barbara A., Haddad, Tufia C., Goetz, Matthew P., Weinshilboum, Richard M., Wang, Liewei
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7655717/
https://ncbi.nlm.nih.gov/pubmed/32649577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000415
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados